HPA005456

antibody from Atlas Antibodies

Targeting: ARID1A B120, BAF250, BAF250a, C10rf4, C1orf4, P270, SMARCF1

Provider product page for HPA005456

Western blot

Immunocytochemistry

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [91]
Comments [0]
Validations [0]

Submit

Product number: HPA005456 - Provider product page
Provider: Atlas Antibodies
Proper citation: Atlas Antibodies Cat#HPA005456, RRID:AB_1078205
Product name: Anti-ARID1A
Antibody type: Polyclonal
Description: Polyclonal Antibody against Human ARID1A, Gene description: AT rich interactive domain 1A (SWI-like), Alternative Gene Names: B120, BAF250, BAF250a, C10rf4, C1orf4, P270, SMARCF1, Validated applications: WB, IHC, ICC, Uniprot ID: O14497, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Reactivity: Human
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 100 µl
Concentration: 0.2 mg/ml
Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Handling: The antibody solution should be gently mixed before use.

ARID1A protein structure - HPA005456 shown in red.

Submitted references ARID1 and BRG1 Expression in Endometrial Cancer

KONTOMANOLIS E, SYMEONIDIS P, NIKOLETTOS K, PERROS P, RODY A, TSIKOURAS P, NIKOLETTOS N, GIATROMANOLAKI A
In Vivo 2024;38(3):1260-1265

ARID1A overexpression inhibits colorectal cancer cell migration through the regulation of epithelial‑mesenchymal transition

Wanna‑Udom S, Aluksanasuwan S, Somsuan K, Mongkolwat W, Sakulsak N
Molecular Medicine Reports 2024;30(5)

Proteomic insights into the regulatory function of ARID1A in colon cancer cells

Aluksanasuwan S, Somsuan K, Wanna‑Udom S, Roytrakul S, Morchang A, Rongjumnong A, Sakulsak N
Oncology Letters 2024;28(2)

ARID1A governs the silencing of sex-linked transcription during male meiosis in the mouse

Menon D, Chakraborty P, Murcia N, Magnuson T
eLife 2024;12

Mitotic bookmarking by SWI/SNF subunits

Zhu Z, Chen X, Guo A, Manzano T, Walsh P, Wills K, Halliburton R, Radko-Juettner S, Carter R, Partridge J, Green D, Zhang J, Roberts C
Nature 2023;618(7963):180-187

Endothelial Arid1a deletion disrupts the balance among angiogenesis, neurogenesis and gliogenesis in the developing brain

Wang Y, Su L, Wang W, Zhao J, Wang Y, Li S, Liu Y, Chai R, Li X, Teng Z, Liu C, Hu B, Ji F, Jiao J
Cell Proliferation 2023;56(5)

Mixed Ovarian Neoplasms With Gastrointestinal-type Mucinous and Mullerian Epithelial Components

Chui M, Ellenson L
American Journal of Surgical Pathology 2023;47(7):756-765

PPARα activator irbesartan suppresses the proliferation of endometrial carcinoma cells via SREBP1 and ARID1A

LU Y, MIYAMOTO T, TAKEUCHI H, TSUNODA F, TANAKA N, SHIOZAWA T
Oncology Research 2023;31(3):239-253

Abnormal chromatin remodeling caused by ARID1A deletion leads to malformation of the dentate gyrus

Liu P, Lu S, Li X, Tang G, Liu X, Dai S, Jiao L, Lin X, Li X, Hu B, Jiao J, Teng Z, Han C, Liu C
Cell Death & Differentiation 2023;30(9):2187-2199

Comparison of the mutation patterns between tumor tissue and cell-free DNA in stage IV gastric cancer

Kung C, Fang W, Hung Y, Huang K, Chen M, Chao Y, Lin S, Li A, Lo S, Wu C
Aging 2023;15(3):777-790

Simpkins F, Kinose Y, Xu H, Kim H, Kumar S, Shan X, Geroge E, Wang X, Medvedev S, Ferman B, Gitto S, Whicker M, D.Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, Schwartz L, Hwang W, Nathanson K, Mills G, Velculescu V, Wang T, Brown E, Drapkin R
2023

Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma—rationale for targeting ARID1A deficiency

Dong X, Song S, Li Y, Fan Y, Wang L, Wang R, Huo L, Scott A, Xu Y, Pizzi M, Ma L, Wang Y, Jin J, Zhao W, Yao X, Johnson R, Wang L, Wang Z, Peng G, Ajani J
Gut 2022;71(3):467-478

Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors

Momeni Boroujeni A, Kertowidjojo E, Wu X, Soslow R, Chiang S, Da Silva E, Weigelt B, Chui M
Modern Pathology 2022;35(11):1684-1694

Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma

Hamilton S, Tinker A, Kwon J, Lim P, Kong I, Sihra S, Koebel M, Lee C
Journal of Gynecologic Oncology 2022;33(3)

GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors

Clemente V, Hoshino A, Shetty M, Nelson A, Erickson B, Baker R, Rubin N, Khalifa M, Weroha S, Lou E, Bazzaro M
Cancer Research Communications 2022;2(8):784-794

Acetate supplementation restores cognitive deficits caused by ARID1A haploinsufficiency in excitatory neurons

Liu P, Dai S, Mi T, Tang G, Wang Z, Wang H, Du H, Tang Y, Teng Z, Liu C
EMBO Molecular Medicine 2022;14(12)

Targeting USP9X–AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma

Zhang F, Ni Q, Wang K, Cao H, Guan D, Zhang E, Ma N, Wang Y, Zheng Q, Xu S, Zhu B, Chen T, Xia J, Qiu X, Ding X, Jiang H, Qiu L, Wang X, Chen W, Cheng S, Xie D, Li J
Cellular and Molecular Gastroenterology and Hepatology 2022;14(1):101-127

Multidimensional chromatin profiling of zebrafish pancreas to uncover and investigate disease-relevant enhancers

Bordeira-Carriço R, Teixeira J, Duque M, Galhardo M, Ribeiro D, Acemel R, Firbas P, Tena J, Eufrásio A, Marques J, Ferreira F, Freitas T, Carneiro F, Goméz-Skarmeta J, Bessa J
Nature Communications 2022;13(1)

ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression

Li N, Liu Q, Han Y, Pei S, Cheng B, Xu J, Miao X, Pan Q, Wang H, Guo J, Wang X, Zhang G, Lian Y, Zhang W, Zang Y, Tan M, Li Q, Wang X, Xiao Y, Hu G, Jiang J, Huang H, Qin J
Nature Communications 2022;13(1)

Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma

Kao C, Liu C, Lin H, Huang Y, Lan J, Ou Y, Fu H, Wu C
Frontiers in Immunology 2022;13

Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma

Tessiri S, Techasen A, Kongpetch S, Namjan A, Loilome W, Chan-on W, Thanan R, Jusakul A
PeerJ 2022;10

mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma

Zhang S, Zhou Y, Cao J, Burley S, Wang H, Zheng X
Cancer Research 2021;81(22):5652-5665

Arid1a regulates neural stem/progenitor cell proliferation and differentiation during cortical development

Liu X, Dai S, Liu P, Liu C
Cell Proliferation 2021;54(11)

Acute depletion of the ARID1A subunit of SWI/SNF complexes reveals distinct pathways for activation and repression of transcription

Blümli S, Wiechens N, Wu M, Singh V, Gierlinski M, Schweikert G, Gilbert N, Naughton C, Sundaramoorthy R, Varghese J, Gourlay R, Soares R, Clark D, Owen-Hughes T
Cell Reports 2021;37(5):109943

Endometrial Tumor Classification by Histomorphology and Biomarkers in the Nurses’ Health Study

Watkins J, Downing M, Crous-Bou M, Busch E, Chen M, De Vivo I, Mutter G, Antwi S
Journal of Cancer Epidemiology 2021;2021

Neo-Fs Index: A Novel Immunohistochemical Biomarker Panel Predicts Survival and Response to Anti-Angiogenetic Agents in Clear Cell Renal Cell Carcinoma

Kim J, Park J, Shin S, Lim B, Go H
Cancers 2021;13(6):1199

Dedifferentiated Endometrioid Carcinomas with Neuroendocrine Differentiation: A Clinicopathological and Immunohistochemical Study of Three Cases

Zhou F, Zhang X, Chen H, Zheng W
Cancer Management and Research 2020;Volume 12

Downregulation of ARID1A is correlated with poor prognosis in non-small cell lung cancer

Wang T, Guo J, Liu W, Guo Q, Cheng L, Zheng R, Hu X
Translational Cancer Research 2020;9(8):4896-4905

ARID1A alterations and their clinical significance in cholangiocarcinoma

Namjan A, Techasen A, Loilome W, Sa-ngaimwibool P, Jusakul A
PeerJ 2020;8

SWI/SNF‐deficiency defines highly aggressive undifferentiated endometrial carcinoma

Tessier‐Cloutier B, Coatham M, Carey M, Nelson G, Hamilton S, Lum A, Soslow R, Stewart C, Postovit L, Köbel M, Lee C
The Journal of Pathology: Clinical Research 2020;7(2):144-153

ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response

Nagarajan S, Rao S, Sutton J, Cheeseman D, Dunn S, Papachristou E, Prada J, Couturier D, Kumar S, Kishore K, Chilamakuri C, Glont S, Archer Goode E, Brodie C, Guppy N, Natrajan R, Bruna A, Caldas C, Russell A, Siersbæk R, Yusa K, Chernukhin I, Carroll J
Nature Genetics 2020;52(2):187-197

Atypical magnetic resonance imaging features and differential diagnosis of hepatocellular carcinoma

Wang S, Yin L, Wang C, Ma M
Journal of International Medical Research 2020;48(10)

Endometrial Carcinomas with a “Serous” Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations

Conlon N, Da Cruz Paula A, Ashley C, Segura S, De Brot L, da Silva E, Soslow R, Weigelt B, DeLair D
American Journal of Surgical Pathology 2020;44(5):641-648

Primary peritoneal clear cell carcinoma. A case report and literature review

Peiro G, Silva-Ortega S, Garcia-Espasa C, Sala-Ferichola M, Perez-Vicente S, Castellon-Molla E, Marcos-Sanmartin J
Gynecologic Oncology Reports 2020;32

Altered ARID1A expression in colorectal cancer

Erfani M, Hosseini S, Mokhtari M, Zamani M, Tahmasebi K, Alizadeh Naini M, Taghavi A, Carethers J, Koi M, Brim H, Mokarram P, Ashktorab H
BMC Cancer 2020;20(1)

Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line

Christie E, Wang Y, Tao V, Shin C, Salamanca C, Chen S, Chow C, Köbel M, Ben-Neriah S, Farnell D, Steidl C, Mcalpine J, Gilks C, Huntsman D
PLOS ONE 2020;15(10):e0240412

Loss of Arid1a Promotes Neuronal Survival Following Optic Nerve Injury

Peng X, Dai S, Li C, Liu P, Wang Z, Du H, Teng Z, Yang S, Liu C
Frontiers in Cellular Neuroscience 2020;14

Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming

Suryo Rahmanto Y, Shen W, Shi X, Chen X, Yu Y, Yu Z, Miyamoto T, Lee M, Singh V, Asaka R, Shimberg G, Vitolo M, Martin S, Wirtz D, Drapkin R, Xuan J, Wang T, Shih I
Nature Communications 2020;11(1)

ARID1A protein expression is retained in ovarian endometriosis with ARID1A loss-of-function mutations: implication for the two-hit hypothesis

Yachida N, Yoshihara K, Suda K, Nakaoka H, Ueda H, Sugino K, Yamaguchi M, Mori Y, Yamawaki K, Tamura R, Ishiguro T, Isobe M, Motoyama T, Inoue I, Enomoto T
Scientific Reports 2020;10(1)

Dual ARID1A/ARID1B loss leads to rapid carcinogenesis and disruptive redistribution of BAF complexes

Wang Z, Chen K, Jia Y, Chuang J, Sun X, Lin Y, Celen C, Li L, Huang F, Liu X, Castrillon D, Wang T, Zhu H
Nature Cancer 2020;1(9):909-922

ARID1A upregulation predicts better survival in patients with urothelial bladder carcinoma

Cao Q, Wang C, Ding Y, Xu D, Qian S, Shen H, Qi J
Journal of International Medical Research 2019;48(4)

Iatrogenic endometriosis harbors somatic cancer-driver mutations

Lac V, Verhoef L, Aguirre-Hernandez R, Nazeran T, Tessier-Cloutier B, Praetorius T, Orr N, Noga H, Lum A, Khattra J, Prentice L, Co D, Köbel M, Mijatovic V, Lee A, Pasternak J, Bleeker M, Krämer B, Brucker S, Kommoss F, Kommoss S, Horlings H, Yong P, Huntsman D, Anglesio M
Human Reproduction 2019;34(1):69-78

T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers

Asaka S, Yen T, Wang T, Shih I, Gaillard S
Modern Pathology 2019;32(4):576-584

ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness

Luo Q, Wu X, Chang W, Zhao P, Nan Y, Zhu X, Katz J, Su D, Liu Z
Cell Death & Differentiation 2019;27(6):1981-1997

FET family fusion oncoproteins target the SWI / SNF chromatin remodeling complex

Lindén M, Thomsen C, Grundevik P, Jonasson E, Andersson D, Runnberg R, Dolatabadi S, Vannas C, Luna Santamarίa M, Fagman H, Ståhlberg A, Åman P
EMBO reports 2019;20(5)

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

Farnaby W, Koegl M, Roy M, Whitworth C, Diers E, Trainor N, Zollman D, Steurer S, Karolyi-Oezguer J, Riedmueller C, Gmaschitz T, Wachter J, Dank C, Galant M, Sharps B, Rumpel K, Traxler E, Gerstberger T, Schnitzer R, Petermann O, Greb P, Weinstabl H, Bader G, Zoephel A, Weiss-Puxbaum A, Ehrenhöfer-Wölfer K, Wöhrle S, Boehmelt G, Rinnenthal J, Arnhof H, Wiechens N, Wu M, Owen-Hughes T, Ettmayer P, Pearson M, McConnell D, Ciulli A
Nature Chemical Biology 2019;15(7):672-680

Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers

Uncel M, Diniz G, Akoz G, Yildirim Ekin Z, Saydan S, Yardim S, Salimoglu S
European Journal of Breast Health 2019;15(2):125-129

Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma

Zhou H, Tan S, Li H, Lin X
Molecular Medicine Reports 2019

Alpha-oxoglutarate inhibits the proliferation of immortalized normal bladder epithelial cells via an epigenetic switch involving ARID1A

Shahid M, Gull N, Yeon A, Cho E, Bae J, Yoon H, You S, Yoon H, Kim M, Berman B, Kim J
Scientific Reports 2018;8(1)

The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ

Chang L, Azzolin L, Di Biagio D, Zanconato F, Battilana G, Lucon Xiccato R, Aragona M, Giulitti S, Panciera T, Gandin A, Sigismondo G, Krijgsveld J, Fassan M, Brusatin G, Cordenonsi M, Piccolo S
Nature 2018;563(7730):265-269

Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer

Visser N, van der Wurff A, Pijnenborg J, Massuger L, Bulten J, Nagtegaal I
Virchows Archiv 2018;472(3):407-413

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers

Khalique S, Naidoo K, Attygalle A, Kriplani D, Daley F, Lowe A, Campbell J, Jones T, Hubank M, Fenwick K, Matthews N, Rust A, Lord C, Banerjee S, Natrajan R
The Journal of Pathology: Clinical Research 2018;4(3):154-166

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

Berns K, Caumanns J, Hijmans E, Gennissen A, Severson T, Evers B, Wisman G, Jan Meersma G, Lieftink C, Beijersbergen R, Itamochi H, van der Zee A, de Jong S, Bernards R
Oncogene 2018;37(33):4611-4625

Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma

Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, O'Neill R, Solomides C, Peiper S, Testa J, Uzzo R, Yang H
Oncotarget 2017;8(23):37423-37434

Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma

Walter D, Venancio O, Buza E, Tobias J, Deshpande C, Gudiel A, Kim-Kiselak C, Cicchini M, Yates T, Feldser D
Cancer Research 2017;77(7):1719-1729

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression

Howitt B, Strickland K, Sholl L, Rodig S, Ritterhouse L, Chowdhury D, D'Andrea A, Matulonis U, Konstantinopoulos P
OncoImmunology 2017;6(2):e1277308

Cancer-Associated Mutations in Endometriosis without Cancer

Anglesio M, Papadopoulos N, Ayhan A, Nazeran T, Noë M, Horlings H, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu R, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen J, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood L, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler K, Gilks C, Diaz L, Wang T, Vogelstein B, Yong P, Huntsman D, Shih I
New England Journal of Medicine 2017;376(19):1835-1848

Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer

Sun X, Wang S, Wei Y, Luo X, Jia Y, Li L, Gopal P, Zhu M, Nassour I, Chuang J, Maples T, Celen C, Nguyen L, Wu L, Fu S, Li W, Hui L, Tian F, Ji Y, Zhang S, Sorouri M, Hwang T, Letzig L, James L, Wang Z, Yopp A, Singal A, Zhu H
Cancer Cell 2017;32(5):574-589.e6

Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups

Parra-Herran C, Lerner-Ellis J, Xu B, Khalouei S, Bassiouny D, Cesari M, Ismiil N, Nofech-Mozes S
Modern Pathology 2017;30(12):1748-1759

Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing – a case report

Valtcheva N, Lang F, Noske A, Samartzis E, Schmidt A, Bellini E, Fink D, Moch H, Rechsteiner M, Dedes K, Wild P
BMC Cancer 2017;17(1)

Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment

Llorca-Cardeñosa M, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, Navarro L, Gambardella V, Castillo J, Roselló S, Navarro S, Ribas G, Cervantes A
Oncotarget 2016;7(39):63424-63436

ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance

Lee L, Sadot E, Ivelja S, Vakiani E, Hechtman J, Sevinsky C, Klimstra D, Ginty F, Shia J
Human Pathology 2016;53

Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells

Rahmanto Y, Jung J, Wu R, Kobayashi Y, Heaphy C, Meeker A, Wang T, Shih I
Journal of Biological Chemistry 2016;291(18):9690-9699

Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas

Coatham M, Li X, Karnezis A, Hoang L, Tessier-Cloutier B, Meng B, Soslow R, Blake Gilks C, Huntsman D, Stewart C, Postovit L, Köbel M, Lee C
Modern Pathology 2016;29(12):1586-1593

Molecular genetic heterogeneity in undifferentiated endometrial carcinomas

Rosa-Rosa J, Leskelä S, Cristóbal-Lana E, Santón A, López-García M, Muñoz G, Pérez-Mies B, Biscuola M, Prat J, Esther O, Soslow R, Matias-Guiu X, Palacios J
Modern Pathology 2016;29(11):1390-1398

Suppression of the SWI/SNF Component Arid1a Promotes Mammalian Regeneration

Sun X, Chuang J, Kanchwala M, Wu L, Celen C, Li L, Liang H, Zhang S, Maples T, Nguyen L, Wang S, Signer R, Sorouri M, Nassour I, Liu X, Xu J, Wu M, Zhao Y, Kuo Y, Wang Z, Xing C, Zhu H
Cell Stem Cell 2016;18(4):456-466

Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma

Samant R, Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, Liao L, Cho E, O'Neill R, Solomides C, Peiper S, Testa J, Uzzo R, Yang H
PLOS ONE 2016;11(10):e0164554

Altered expression of AT-rich interactive domain 1A in hepatocellular carcinoma.

Abe H, Hayashi A, Kunita A, Sakamoto Y, Hasegawa K, Shibahara J, Kokudo N, Fukayama M
International journal of clinical and experimental pathology 2015;8(3):2763-70

Deregulation ofARID1A,CDH1,cMETandPIK3CAand target-related microRNA expression in gastric cancer

Ibarrola-Villava M, Llorca-Cardeñosa M, Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo J, Roselló S, Navarro S, Ribas G, Cervantes A
Oncotarget 2015;6(29):26935-26945

Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases

Faraj S, Chaux A, Gonzalez-Roibon N, Munari E, Cubilla A, Shih I, Netto G
Human Pathology 2015;46(5):761-766

Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma

He F, Li J, Xu J, Zhang S, Xu Y, Zhao W, Yin Z, Wang X
Journal of Experimental & Clinical Cancer Research 2015;34(1)

ARID1A expression in gastric adenocarcinoma: Clinicopathological significance and correlation with DNA mismatch repair status

Inada R, Sekine S, Taniguchi H, Tsuda H, Katai H, Fujiwara T, Kushima R
World Journal of Gastroenterology 2015;21(7):2159-2168

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

Bitler B, Aird K, Garipov A, Li H, Amatangelo M, Kossenkov A, Schultz D, Liu Q, Shih I, Conejo-Garcia J, Speicher D, Zhang R
Nature Medicine 2015;21(3):231-238

Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas

Müller R, Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, Hagiwara O, Tanikawa M, Maeda D, Hasegawa K, Nakagawa S, Wada-Hiraike O, Kawana K, Fukayama M, Fujiwara K, Yano T, Osuga Y, Fujii T, Aburatani H
PLOS ONE 2015;10(6):e0128066

Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors

Ayhan A, Mao T, Suryo Rahmanto Y, Zeppernick F, Ogawa H, Wu R, Wang T, Shih I
The Journal of Pathology: Clinical Research 2015;1(3):186-193

Application of ARID1A to murine formalin-fixed paraffin embedded tissue using immunohistochemistry

Howat W, Miller J, Gounaris I
F1000Research 2014;3

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma

Huang H, Lin M, Huang W, Chiang Y, Kuo K
Modern Pathology 2014;27(7):983-990

Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy

Wu R, Ayhan A, Maeda D, Kim K, Clarke B, Shaw P, Chui M, Rosen B, Shih I, Wang T
The Journal of Pathology 2014;232(4):473-481

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation

Wiegand K, Hennessy B, Leung S, Wang Y, Ju Z, McGahren M, Kalloger S, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio M, Gilks B, Mills G, Huntsman D, Carey M
BMC Cancer 2014;14(1)

Loss of ARID1A Expression Correlates With Stages of Tumor Progression in Uterine Endometrioid Carcinoma

Mao T, Ardighieri L, Ayhan A, Kuo K, Wu C, Wang T, Shih I
American Journal of Surgical Pathology 2013;37(9):1342-1348

Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett’s esophagus

Streppel M, Lata S, DelaBastide M, Montgomery E, Wang J, Canto M, Macgregor-Das A, Pai S, Morsink F, Offerhaus G, Antoniou E, Maitra A, McCombie W
Oncogene 2013;33(3):347-357

Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.

Xiao W, Awadallah A, Xin W
International journal of clinical and experimental pathology 2012;5(7):642-50

Endocervical-type Mucinous Borderline Tumors are Related to Endometrioid Tumors Based on Mutation and Loss of Expression of ARID1A

Wu C, Mao T, Vang R, Ayhan A, Wang T, Kurman R, Shih I
International Journal of Gynecological Pathology 2012;31(4):297-303

Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O
Modern Pathology 2012;25(4):615-624

Loss of ARID1A Expression Is an Early Molecular Event in Tumor Progression From Ovarian Endometriotic Cyst to Clear Cell and Endometrioid Carcinoma

Ayhan A, Mao T, Seckin T, Wu C, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman R, Shih I
International Journal of Gynecological Cancer 2012;22(8):1310-1315

Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation

Weigert O, Kopp N, Lane A, Yoda A, Dahlberg S, Neuberg D, Bahar A, Chapuy B, Kutok J, Longtine J, Kuo F, Haley T, Salois M, Sullivan T, Fisher D, Fox E, Rodig S, Antin J, Weinstock D
Cancer Discovery 2012;2(1):47-55

Functional Analysis of In-frame Indel ARID1A Mutations Reveals New Regulatory Mechanisms of Its Tumor Suppressor Functions

Guan B, Gao M, Wu C, Wang T, Shih I
Neoplasia 2012;14(10):986-993

Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.

Guan B, Gao M, Wu CH, Wang TL, Shih IeM
Neoplasia (New York, N.Y.) 2012 Oct;14(10):986-93

PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O
Virchows Archiv 2011;460(1):77-87

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer

Wang K, Kan J, Yuen S, Shi S, Chu K, Law S, Chan T, Kan Z, Chan A, Tsui W, Lee S, Ho S, Chan A, Cheng G, Roberts P, Rejto P, Gibson N, Pocalyko D, Mao M, Xu J, Leung S
Nature Genetics 2011;43(12):1219-1223

Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma

Guan B, Mao T, Panuganti P, Kuhn E, Kurman R, Maeda D, Chen E, Jeng Y, Wang T, Shih I
American Journal of Surgical Pathology 2011;35(5):625-632

No comments: Submit comment

No validations: Submit validation data